PRI-002
Priavoid has successfully applied to start a Phase I clinical trial with PRI-002, a drug for the causal treatment of Alzheimer’s disease. A Phase II clinical trial is in preparation and is scheduled to start in 2018.
News & Events:
Priavoid has successfully applied to start a Phase I clinical trial with PRI-002, a drug for the causal treatment of Alzheimer’s disease. A Phase II clinical trial is in preparation and is scheduled to start in 2018.
Cookie Preference
Please select an option. You can find more information about the consequences of your choice at Help.
Select an option to continue
Your selection was saved!
Help
Help
To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.
You can change your cookie setting here anytime: Privacy Policy. Legal Notice
Back